Invitae (NVTA) is at the forefront of the genetic testing industry. The company is part of a growing effort to push genetics into mainstream medicine. While genetics is still an emerging field, it is one of the most promising in medicine. Invitae is capitalizing on the convergence of technology and medicine in hopes of revolutionizing genomics.
The stock has completely rebounded from the negative impacts of the coronavirus. The company is now near record-level highs.
Aggressively Expanding
Invitae is currently one of the fastest-growing companies in the genetics industry. It